Cas:1187926-84-6 1H-BenziMidazole, 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-1-(2,2,2-trifluoroethyl)- manufacturer & supplier

Chemical Name:1H-BenziMidazole, 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-1-(2,2,2-trifluoroethyl)-

CAS.NO:1187926-84-6

Synonyms:1H-BenziMidazole, 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-1-(2,2,2-trifluoroethyl)-

Molecular Formula:C₁₈H₁₅F₆N₃O₂S

Molecular Weight:451.3860192

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1H-BenziMidazole, 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-1-(2,2,2-trifluoroethyl)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-BenziMidazole, 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-1-(2,2,2-trifluoroethyl)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-BenziMidazole, 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-1-(2,2,2-trifluoroethyl)- Use and application,1H-BenziMidazole, 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-1-(2,2,2-trifluoroethyl)- technical grade,usp/ep/jp grade.

Related News: Schimpke, an assistant professor in the Division of Minimally Invasive and Bariatric Surgery at Rush Medical College in Chicago, and his colleagues point out that obesity is linked to a considerably higher risk for developing upwards of 40 different serious illnesses, including heart disease and diabetes. 1H-BenziMidazole, 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-1-(2,2,2-trifluoroethyl)- manufacturer Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. 1H-BenziMidazole, 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-1-(2,2,2-trifluoroethyl)- supplier Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 1H-BenziMidazole, 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-1-(2,2,2-trifluoroethyl)- vendor Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 1H-BenziMidazole, 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-1-(2,2,2-trifluoroethyl)- factory Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.